Armistice Capital Master Fund Ltd.
SEC CIK 1633584 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | Dir, 10% | 1.67M | $756.6K | $2.16M | 3 | 2022-01-07 | 2023-06-26 |
Most active insiders at AVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Sullivan Christopher Ryan | CFO | — | $3.72M |
| 2 | Doyle Mittie | Chief Medical Off | — | $2.98M |
| 3 | VARKI PAUL | CLO | — | $1.51M |
| 4 | Goldman Jonathan | Dir | — | $163.0K |
| 5 | Chan Mitchell | Dir | — | $72.5K |
| 6 | Riley Jennifer | Chief Strategy Off | — | $52.0K |
| 7 | Truex Samantha | Dir | — | — |
| 8 | KANTOFF AARON | Dir | — | — |
| 9 | NEIL GARRY ARTHUR | CEO, Dir | — | — |
| 10 | KAPLAN GILLA | Dir | — | — |
Armistice Capital Master Fund Ltd. made no open-market trades at AVTX in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2023-06-28 | 2023-06-26+ | AVTX | Avalo Therapeutics, Inc. | Armistice Capital Master Fund Ltd. | 10% | S - Sale | $0.5871 | -3.68M | 1.67M | -69% | -$2.16M |
| MI | 2022-02-28 | 2022-02-24+ | AVTX | Avalo Therapeutics, Inc. | Armistice Capital Master Fund Ltd. | Dir, 10% | P - Purchase | $0.7971 | +140.0K | 46.84M | +0.3% | +$111.6K |
| MI | 2022-01-11 | 2022-01-07+ | AVTX | Avalo Therapeutics, Inc. | Armistice Capital Master Fund Ltd. | Dir, 10% | P - Purchase | $0.9999 | +645.0K | 45.63M | +1% | +$645.0K |
Purchase Sale Sale after option exercise All abbreviations